Navigate Up
UPMC/University of Pittsburgh Schools of the Health Sciences
Manager
Telephone: 412-647-9966

Director
Telephone: 412-417-2582
 

UPMC Media Relations

UPMC Uses New Technology to Treat Aortic Heart Valve Disease without Open Heart Surgery

PITTSBURGH, March 22, 2011 – UPMC has performed its first patient implants in the Medtronic CoreValve® U.S. Clinical Trial to evaluate a non-surgical, less-invasive procedure as a treatment alternative to open-heart surgery for patients who suffer from a serious narrowing of the heart’s aortic valve.

UPMC is one of 40 hospitals across the U.S. to participate in the trial for patients with severe aortic stenosis, which prevents the heart’s aortic valve from opening completely and in turn hampers healthy blood flow from the aorta to the rest of the body. Untreated, it can lead to serious heart problems.

A 66-year-old man, from New Alexandria, Pa., was one of the first patients at UPMC to receive the CoreValve implant. He suffered shortness of breath, which worsened when climbing stairs, and required oxygen nearly around-the-clock because of his aortic stenosis.

In January, physicians channeled a catheter through a small opening in his femoral artery to reach the heart. The physician then guided the CoreValve System to the aortic valve, where the valve self-expanded to replace the diseased aortic valve; the procedure was completed without open-heart surgery or surgical removal of the aortic valve.

“Now I’m practically not using oxygen at all,” the patient said.

His procedure was performed by William Anderson, M.D., director of Interventional Cardiology at UPMC, and Thomas Gleason, M.D., director of the Center for Thoracic Aortic Disease of the UPMC Department of Cardiothoracic Surgery.

“Aortic stenosis frequently occurs in elderly patients who have a higher risk of complications from standard valve-replacement surgery. This growing patient population may then have the most to gain from new, less invasive, catheter-based approaches to the implantation of a new aortic valve. The trial will allow us to explore this possibility,” Dr. Anderson said.

Worldwide, approximately 300,000 people have been diagnosed with this condition (100,000 in the U.S.), and approximately one-third of these patients are deemed at too high a risk for open-heart surgery, the only therapy with significant clinical effect that currently is available in the United States.

“Because open-heart surgery is currently the only available treatment option for these patients, and because the risks of surgery can be significant for many patients, the medical community is enthusiastic about the less-invasive option,” Dr. Gleason said.

In the U.S., the CoreValve System will not be commercially available until the successful completion of this clinical trial and approval by the U.S. Food and Drug Administration. The CoreValve System received CE (Conformité Européenne) Mark in Europe in 2007.

For more information about the Medtronic CoreValve U.S. Clinical Trial, visit www.aorticstenosistrial.com.

Physicians are available for interviews to discuss the clinical trial. Broadcast quality animation also is available.

Information about the clinical trial is available at www.clinicaltrials.gov.

#  #  #

About UPMC

UPMC is an $8 billion global health enterprise with almost 50,000 employees headquartered in Pittsburgh, Pa., and is transforming health care by integrating 20 hospitals, 400 doctors’ offices and outpatient sites, a health insurance services division, and international and commercial services. Affiliated with the University of Pittsburgh Schools of the Health Sciences, UPMC is redefining health care by using innovative science, technology and medicine to invent new models of accountable, cost-efficient and patient-centered care. For more information on how UPMC is taking medicine from where it is to where it needs to be, go to www.upmc.com.

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com